Table. Meta-regression From Frequentist and Bayesian Models.

No. of Studies in Bayesian/Frequentist Analyses (n = 34/n = 18)	Covariate	Frequentist Model		Bayesian Model
		OR (95% CI)	P Valuea	OR (95% CrI)	Probability Relative OR ≤ 1.00b
Diagnosis
6/3	AMD	1.01 (0.46-2.20)	1 [Reference]	0.98 (0.33-3.41)	1 [Reference]
15/11	DME	1.68 (1.01-2.77)	.17	1.75 (0.94-3.85)	0.15
13/4	RVO	0.45 (0.09-2.17)	.72	0.30 (0.03-2.25)	0.82
No. of injections
33/17	Per 1 more	1.12 (1.04-1.22)	.005	1.06 (0.98-1.15)	0.06
Drug
18/6	Ranibizumab	1.44 (0.72-2.87)	1 [Reference]	1.75 (0.74-4.82)	1 [Reference]
6/1	Bevacizumab	0.66 (0.03-14.6)	.65	24.4 (0.10-∞)	0.24
3/1	Pegaptanib sodium	1.00 (0.39-2.21)	.64	1.03 (0.21-4.97)	0.74
6/10	Aflibercept	1.47 (0.79-2.72)	.56	1.46 (0.61-3.23)	0.62
Follow-up, mo
14/5	6 (6-8)	0.65 (0.16-2.66)	1 [Reference]	0.82 (0.15-6.53)	1 [Reference]
15/8	12 (11-12)	1.02 (0.54-1.92)	.83	1.07 (0.51-2.46)	0.41
5/5	24 (23-24)	1.89 (1.06-3.36)	.17	2.07 (1.06-4.49)	0.21
Previous cardiovascular disease
15/7	No	1.12 (0.70-2.06)	1 [Reference]	1.23 (0.52-3.22)	1 [Reference]
18/11	Yes	2.12 (0.56-8.08)	.14	1.50 (0.41-4.72)	0.24

Abbreviation: OR, odds ratio.

^aCalculated for the comparison of the ORs of death in the subgroup compared with that in the reference category.

^bIndicates probability that the relative OR for the category is more than 1.00 compared with the reference category.